Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
It’s interesting to look back at the history of the BAT share price and dividend history.
I see strong parallels, obviously there were strong reasons not to invest in a company who’s product kills people but there was a lot of cash coming in despite high excise duties in their case.
20 years ago the share price had already doubled from its low to the £6.00 area but it kept rising to over £50 , its around £27 now but has been paying dividends of about or over £2.00 a year for years
I can’t see poorer nations taxing coal like tobacco as that would negate the advantage of cheap power/ energy.
Basically my point is, whilst we might not be in fashion and the future might not be coal forever, that was a mistake to avoid tobacco stocks 20 years ago as they are still doing well and coal could be a very similar story.
And where there’s muck there’s brass.
Not everyone is as bothered about climate change as some of the hand wringers in the west and the transition away from coal could be held up for years as blue hydrogen is too expensive and not carbon friendly itself.
The problems will persist into the next financial year because they have problems now and their current year ( to the end of September) is nearly over. The problems might not persist for long into the next financial year though. The share price is less than half what it was when the issues first emerged and current trading is good with a ‘record order book’ and management are confident the issues will be resolved. The world is becoming more insecure and the demand for Avon’s products will still be there.
I think there is a good chance this will move higher again soon as EAH sales were very strong (and continue to be) despite multiple ASF outbreaks in China. If and when these outbreaks are brought under control sales should increase again. Also there could be news on vaccine development anytime.
AIVLOSIN, is the flagship product which EAH own and I believe it is selling extremely well almost worldwide with excellent growth still to add. There are more medications in the pipeline. On our own I am sure we will do very well but I wouldn’t be surprised if larger companies are looking at our products with envy and a bid for the whole company or some products could easily be forthcoming.